Funding of £5m will create new jobs in Norfolk

Published: 28-Jan-2010
Manufacturing Research & Development Finance Pharmaceutical

Thirty new laboratories and offices for 300 research scientists are to be built in Norfolk, UK

Thirty new laboratories and offices for 300 research scientists are to be built in Norfolk, UK with £5m of funding from a partnership including the Biotechnology and Biological Sciences Research Council (BBSRC).

The new development will be based at Norwich Science Park and provide facilities for start-up and expanding businesses.

BBSRC will provide £500,000 as well as the land and buildings to host the new facilities, with £1.4m coming from the East of England Development Agency (EEDA), £1m from the Greater Norwich Development Partnership (GNDP), £500,000 from NRP partner the University of East Anglia (UEA), and the remainder from other NRP partners.

The new facilities, to be opened in July, will be managed by a new joint venture company called Colney Innovations (CIL).

David Parfrey, BBSRC director of finance and director of CIL, said: "The research carried out by the 2,000 scientists already working at Norwich Science Park is world-class and it makes absolute sense to create a facility on this site where the results of such research can be taken through to applications."

Prof Douglas Kell, chief executive of BBSRC, added: "The Norwich Research Park is home to three world-class BBSRC institutes: the John Innes Centre, the Institute of Food Research and The Genome Analysis Centre. This new facility will play a key role in helping our scientists, and others, to translate their excellent science into products to benefit the economy and people of the UK."




See more

You may also like

Manufacturing

Symeres expands spray drying capabilities at Cranbury CMC site for poorly soluble drug candidates

Read more
The investment integrates ASD development, formulation sciences, and analytical characterisation under one roof — supporting BCS Class II and IV compounds from preclinical screening through to Phase II clinical materials

Trending Articles

  1. Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
  2. GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
  4. Safe and accurate flow measurement for pharmaceutical production Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
  5. UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Symeres expands spray drying capabilities at Cranbury CMC site for poorly soluble drug candidates

The investment integrates ASD development, formulation sciences, and analytical characterisation under one roof — supporting BCS Class II and IV compounds from preclinical screening through to Phase II clinical materials
Regulatory

MHRA approves first oral semaglutide tablet for weight loss in the UK

Novo Nordisk's Wegovy tablet becomes the UK's first GLP-1 receptor agonist in oral form for obesity treatment — a significant shift in delivery format as the drug awaits NICE evaluation for NHS access
Manufacturing

Reacta Healthcare secures expanded MHRA GMP certification covering in-house analytical testing

The renewed licence strengthens the OFC material manufacturer's quality oversight across its clinical trial supply chain, reinforcing its position as the only pharmaceutical GMP-compliant oral food challenge supplier operating globally
Finance

ARK Invest backs Cellares to mass manufacture cell therapies with $20m investment

The ARK Venture Fund has previously invested in tech platforms such as OpenAI and Anthropic and is now backing the life sciences company to solve cell therapy's scaling problem
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

PhoreMost announces PMC-001 as lead oncology programme

The biotech will advance the small molecule towards Phase I trials, positioning it for the treatment of primary and secondary brain cancers. Dr Gabriel Fox will also join the company as Consulting Chief Medical Officer to lead the clinical development of the molecule
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Where nanoengineering meets drug formulation

How Nanexa is turning short-acting drugs into long-acting injectables
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Subscribe now